Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04300244
Title Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
Acronym NIPU
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aslaug Helland
Indications
Therapies
Age Groups: adult | senior
Covered Countries SWE | NOR | ESP | DNK | AUS


No variant requirements are available.